View Study [5]"Efficacy and safety of CagriSema in type 2 diabetes" Frias JP et al., 2023 Finding: In people with type 2 diabetes, CagriSema achieved 15.6% weight loss versus 5.1% with semaglutide alone over 32 weeks, with comparable HbA1c reductions and good tolerability
If youre reading this review and still thinking about whether to go for itjust do it
Izadi M, Sadri N, Abdi A, Zadeh MMR, Jalaei D, Ghazimoradi MM, et al
Retatrutides safety profile is consistent with whats already been observed GLP-1 receptor agonists and combined GLP-1/GIP receptor agonists, meaning the expected side effects are primarily gastrointestinal (GI) in nature: Nausea, vomiting, diarrhea, and constipation
What Are Peptides, and What's the Hype